Stock Analysis on Net

Illumina Inc. (NASDAQ:ILMN)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 5, 2021.

Current Ratio
since 2005

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Illumina Inc., current ratio, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).

1 US$ in millions


The analysis of the current assets, current liabilities, and current ratio over the observed periods reveals notable trends in liquidity management and financial stability.

Current Assets
There is a consistent upward trend in current assets from 80 million US dollars in early 2006 to 4,483 million US dollars at the end of 2020. The growth is steady, with significant increments especially noticeable from 2017 onwards, where the figures rise sharply from 2,318 million to nearly 4,500 million by 2020. This indicates an increasing ability to cover short-term obligations and an expanding asset base.
Current Liabilities
Current liabilities exhibit more volatility compared to current assets. Starting at 22 million US dollars in 2006, there is a substantial increase up to 510 million by late 2008, followed by fluctuations including a notable peak of 1,804 million in 2018. This peak might indicate a period of increased short-term borrowing or obligations. The values decline in the subsequent years but rise again in 2020. Overall, liabilities demonstrate periods of strain and adjustment.
Current Ratio
The current ratio, a key liquidity indicator, reflects the interplay between current assets and liabilities. It starts relatively high at 3.67 in early 2006 and experiences varied fluctuations over the years. There is a decline to 1.7 in 2008, suggesting tighter liquidity possibly due to the increased liabilities that year. From 2010 to 2013, the ratio stabilizes at relatively high levels between 3.29 and 6.5, indicating strong liquidity positions. A dip is seen again around 2014-2018, coinciding with the spikes in liabilities, lowering the ratio to as low as 2.49 in 2018. By 2020, the current ratio increases again to 3.6, signifying improvement in liquidity.

In summary, the company demonstrates overall growth in current assets, suggesting enhanced capacity to meet short-term obligations. However, fluctuations in current liabilities have intermittently pressured liquidity positions, as reflected in the variable current ratio. The recent years show a recovery in liquidity after periods of elevated short-term liabilities, indicating potentially improved financial management or operational performance.


Comparison to Competitors

Illumina Inc., current ratio, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Illumina Inc., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).


Comparison to Industry (Health Care)